DiagnoCure Labs gets NY state permit

The New York State Department of Health has issued a clinical laboratory permit to DiagnoCure’s (TSX:CUR) Oncology Laboratories unit that allows the lab to test commercial samples originating in New York for the Previstage GCC colorectal staging test.

“Previstage GCC is the only molecular test available to help better identify whether colorectal cancer has spread to regional lymph nodes,” Valerie Palmieri, president of DiagnoCure Oncology Labs, said in a statement.

Dr. Yves Fradet, president and CMO of parent DiagnoCure, added that DiagnoCure Oncology Labs has now obtained all major U.S. clinical laboratory licences and can receive specimens from all 50 states.